Incidence of interstitial lung disease in patients with mesothelioma in the west part of Japan

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 6, 2011, Pages 643-652

  Nojiri, Shuko ^f   Gemba, Kenichi ^a   Aoe, Keisuke ^b   Kato, Katsuya ^c   Yamaguchi, Takuhiro ^d   Sato, Tsugumichi ^e   Kubota, Kiyoshi ^f   Kishimoto, Takumi ^a  

^a OKAYAMA ROSAI HOSPITAL   (Japan)

^b NATIONAL SANYO HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NPO (Nonprofit Organization) Drug Safety Research Unit Japan   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

Incidence; Interstitial lung disease; Mesothelioma; Natural history

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PICIBANIL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; FEMALE; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; JAPAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PLEURODESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; JAPAN; LUNG DISEASES, INTERSTITIAL; MALE; MESOTHELIOMA; MIDDLE AGED; PICIBANIL; PLEURODESIS; POISSON DISTRIBUTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VINBLASTINE;

EID: 79959535388     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2123     Document Type: Article

References (53)

1. Ryu JH, Daniels CE, Hartman TE et al. Diagnosis of interstitial lung diseases. Mayo Clin Proc 2007; 82: 976-986. doi: 10.4065/82.8.976
2. Burkhardt A. Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis 1989; 140: 513-524.
3. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
4. Hubbard R, Lewis S, Richards K et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996; 347: 284-289. doi: 10.1016/S0140-6736(96)90465-1
5. du Bois RM, Wells AU. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur Respir J 2001; 18: 43S-55S.
6. Nicholson AG. Classification of idiopathic interstitial pneumonias: making sense of the alphabet soup. Histopathology 2002; 41: 381- 391. doi: 10.1046/j.1365-2559.2002.01421.x
7. Raghu G, Weycker D, Edelsberg J et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-816. doi: 10.1164/rccm.200602-163OC
8. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338-342. doi: 10.1136/thorax.57.4.338
9. Kolek V. Epidemiology of cryptogenic fibrosing alveolitis in Moravia and Silesia. Acta Univ Palacki Olomuc Fac Med 1994; 137: 49-50.
10. Munakata M, Asakawa M, Hamma Y et al. Present status of idiopathic interstitial pneumonia-from epidemiology to etiology. Nihon Kyobu Shikkan Gakkai Zasshi 1994; 32: 187-192.
11. Demedts M, Wells AU, Antó JM et al. Interstitial lung diseases: an epidemiological overview. Eur Respir J 2001; 32: 2s-16s.
12. Callahan WP, Jr, Sutherland JC, Fulton JK et al. Acute diffuse interstitial fibrosis of the lungs. AMA Arch Intern Med 1952; 90: 468-482.
13. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 2004; 91: S3-S10. doi: 10.1038/sj.bjc.6602061
14. Kawai T, Yakumaru K, Suzuki M et al. Diffuse interstitial pulmonary fibrosis and lung cancer. Acta Pathol Jpn 1987; 37: 11-19.
15. Nakata K, Matsushita H. Coexistence of lung cancer and idiopathic interstitial pneumonia. Jpn J Clin Radiol 1991; 36: 769-774.
16. Turner-Warwick M, Lebowitz M, Burrows B et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35: 496-499. doi: 10.1136/thx.35.8.593
17. Hubbard R, Venn A, Smith C et al. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am J Respir Crit Care Med 1998; 157: 743-747.
18. Kaneda H, Tamura K, Kurata T et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2004; 46: 247-254. doi: 10.1016/j.lungcan.2004.04.032
19. Takano T, Ohe Y, Kusumoto M et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004; 45: 93-104. doi: 10.1016/j.lungcan.2004.01.010
20. Nakase K. Acute interstitial pneumonitis during chemotherapy for haematological malignancy. Eur J Cancer Care 2005; 14: 336-341. doi: 10.1111/j.1365-2354.2005.00589.x
21. Nakajima A, Inoue E, Tanka E et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 2010; 39: 360-367. doi: 10.3109/03009741003604542
22. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004; 91: S18-S23. doi: 10.1038/sj.bjc.6602063
23. Nojiri S, Gemba K, Aoe K et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol 2011; 41: 32-39. doi:10.1093/jjco/hyq159.
24. Steele JP, Klabatsa A, Fennell DA et al. Prognostic factors in mesothelioma. Lung Cancer 2005; 49: S49-S52. doi: 10.1016/j.lungcan.2005.03.009
25. Mullan RJ, Murthy LI. Occupational sentinel health events: an updated list for physician recognition and public health surveillance. Am J Ind Med 1991; 19: 775-799. doi: 10.1002/ajim.4700190610
26. Orenstein MR, Schenker MB. Environmental asbestos exposure and mesothelioma. Curr Opin Pulm Med 2000; 6: 371-377.
27. Vogelzang N, Pass HI. Newer issues in mesothelioma chemotherapy. J Thorac Oncol 2006; 1: 177-179. doi: 10.1097/01243894-200602000-00015
28. Kindler HL, Millard F, Herndon JE, 2nd et al. Gemcitabine for malignant mesothelioma: a phase II trial by the cancer and leukemia group B. Lung Cancer 2001; 31: 311-317. doi: 10.1016/S0169-5002(00)00166-5
29. van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889. doi: 10.1200/JCO.20005.14.589
30. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644. doi: 10.1200/JCO.2003.11.136
31. Hughes RS. Malignant pleural mesothelioma. Am J Med Sci 2005; 329: 29-44.
32. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the international mesothelioma interest group. Chest 1995; 108: 1122-1128. doi: 10.1378/chest.108.4.1122
33. Endo M, Johkoh T, Kimura K et al. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 2006; 52: 135-140. doi: 10.1016/j.lungcan.2006.02.002
34. Raghunathan TE, Lepkowski J, Van Hoewyk J et al. A muitivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 2001; 27: 85-95.
35. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Wiley, New York 1987.
36. Wallace WA, Fitch PM, Simpson AJ et al. Inflammation-associated remodelling and fibrosis in the lung-a process and an end point. Int J Exp Pathol 2007; 88: 103-110. doi: 10.1111/j.1365-2613.2006.00515.x
37. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest 2007; 117: 530-538. doi: 10.1172/JCI30595
38. Vannella KM, Moore BB. Viruses as co-factors for the initiation or exacerbation of lung fibrosis. Fibrogenesis Tissue Repair 2008; 1: 2. doi: 10.1186/1755-1536-1-2
39. Anderson H, Lund B, Bach F et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1821-1826.
40. Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-2736.
41. Carmichael J, Fink U, Russell RC et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101-105.
42. Gupta N, Ahmed I, Steinberg H et al. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol 2002; 25: 96-100. doi: 10.1097/00000421-200202000-00021
43. Pavlakis N, Bell DR, Millward MJ et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291.
44. Takada M, Negoro S, Kudo S et al. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study. Cancer Chemother Pharmacol 1998; 41: 217-222. doi: 10.1007/s002800050731
45. Marruchella A, Fiorenzano G, Merizzi A et al. Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J 1998; 11: 504-506. doi: 10.1183/09031936.98.11020504
46. Vander Els NJ, Miller V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 1998; 114: 1779-1781. doi: 10.1378/chest.114.6.1779
47. Rosado MF, Kett DH, Schein RM et al. Severe pulmonary toxicity in a patient treated with gemcitabine. Am J Clin Oncol 2002; 25: 31-33. doi: 10.1097/00000421-200202000-00005
48. Maniwa K, Tanaka E, Inoue T et al. An autopsy case of acute pulmonary toxicity associated with gemcitabine. Intern Med 2003; 42: 1022-1025. doi: 10.2169/internalmedicine.42.1022
49. Kouroukis C, Hings I. Respiratory failure following vinorelbine tartrate infusion in a patient with non-small cell lung cancer. Chest 1997; 112: 846-848. doi: 10.1378/chest.112.3.846
50. Kutlu CA, Williams EA, Evans TW et al. Acute lung injury and acute respiratory distress syndrome after pulmonary resection. Ann Thorac Surg 2000; 69: 376-380. doi: 10.1016/S0003-4975(99)01090-5
51. Kawasaki H, Nagai K, Yoshida J et al. Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol 2002; 81: 33-37. doi: 10.1002/jso.10145
52. Iwai K, Mori T, Yamada N et al. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 1994; 150: 670-675.
53. Baumgartner KB, Samet JM, Stidley CA et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155: 242-248.